ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, reported financial results for the three-month period ended December 31, 2014 — the second quarter of the Company’s 2015 fiscal year (2QFY2015). For the Company’s quarter ended December 31, 2014 (2QFY2015), ImmunoGen reported net income of $13.6 million, or $0.16 per basic and diluted share, compared to net income of $3.8 million, or $0.04 per basic and diluted share, for the same quarter last year (2QFY2014). Revenues for 2QFY2015 were $48.3 million, compared to $30.1 million for 2QFY2014. Revenues in the current period include $41.4 million of license and milestone fees, compared to $25.7 million in 2QFY2014. The current year fees include $41.4 million of amortization of upfront fees, in aggregate, previously received from Novartis and Lilly that were recognized in 2QFY2015 due to their license activity in the period. On Friday shares of ImmunoGen, Inc. (NASDAQ:IMGN) closed at $7.63. Company’s sales growth for last 5 years was 16.40.
Airbus and The Boeing Company (NYSE:BA) on Friday announced separate orders from All Nippon Airways’ parent company for 15 jets valued at more than $2 billion at list prices. The Boeing Company (NYSE:BA) in last trading activity fell -1.63% to close at $145.37. Company weekly performance is 7.99% while its quarterly performance stands at 18.80%. The Boeing Company (NYSE:BA) is -1.94% away from its 52 week high.
It was reported on 26 January 2015 that Erba Diagnostics, Inc. (NYSEMKT:ERB), strengthened its U.S. distribution network by having entered into a new agreement with Government Scientific Source and having strengthened and expanded the scope of an agreement with an existing, nationally, prominent channel partner. On last trading day ERBA Diagnostics, Inc. (NYSEMKT:ERB) remains unchanged to close at $3.60. Its volatility for the week is 5.37% while volatility for the month is 6.85%. ERB’s sales growth for past 5 years was 6.40% and its EPS growth for past 5 years was 0.00%. ERBA Diagnostics, Inc. (NYSEMKT:ERB) monthly performance is 22.03%.
Merck & Co. Inc. (NYSE:MRK), announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO® for the treatment of acute bacterial skin and skin structure infections in adults. On Friday shares of Merck & Co. Inc. (NYSE:MRK) closed at $60.28. Company’s sales growth for last 5 years was 13.00% and EPS growth for next 5 years is recorded as 5.86%.
It was reported on 21 January 2015 Gildan Activewear Inc. has signed an exclusive partnership with Mossy Oak to produce a variety of items in the activewear, underwear and socks categories. On last trading day Gildan Activewear Inc. (NYSE:GIL) fell -0.34% to close at $58.37. Its volatility for the week is 2.07% while volatility for the month is 2.35%. GIL’s sales growth for past 5 years was 17.80% and its EPS growth for past 5 years was 29.90%. Gildan Activewear Inc. (NYSE:GIL) monthly performance is 3.25%.